Aspira Women’s Health (NASDAQ:AWH) PT Lowered to $3.30

Aspira Women’s Health (NASDAQ:AWHGet Free Report) had its price target cut by Cantor Fitzgerald from $4.00 to $3.30 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 20.66% from the stock’s current price.

Separately, StockNews.com cut shares of Aspira Women’s Health from a “hold” rating to a “sell” rating in a research note on Thursday, March 28th.

Check Out Our Latest Report on AWH

Aspira Women’s Health Stock Performance

Shares of Aspira Women’s Health stock opened at $2.74 on Monday. The company has a market cap of $28.28 million, a P/E ratio of -0.23 and a beta of 1.61. Aspira Women’s Health has a one year low of $2.31 and a one year high of $6.75. The firm has a fifty day moving average of $4.17 and a two-hundred day moving average of $4.23.

Hedge Funds Weigh In On Aspira Women’s Health

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Portside Wealth Group LLC purchased a new position in Aspira Women’s Health during the 2nd quarter valued at about $617,000. Northeast Financial Consultants Inc purchased a new position in Aspira Women’s Health during the 3rd quarter valued at about $126,000. B. Riley Wealth Advisors Inc. increased its holdings in Aspira Women’s Health by 39.0% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 125,374 shares of the company’s stock valued at $672,000 after acquiring an additional 35,177 shares in the last quarter. Perkins Capital Management Inc. purchased a new position in Aspira Women’s Health during the 3rd quarter valued at about $268,000. Finally, Citadel Advisors LLC increased its holdings in Aspira Women’s Health by 66.2% during the 2nd quarter. Citadel Advisors LLC now owns 252,841 shares of the company’s stock valued at $149,000 after acquiring an additional 100,727 shares in the last quarter. 12.19% of the stock is owned by institutional investors and hedge funds.

Aspira Women’s Health Company Profile

(Get Free Report)

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.

Featured Articles

Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.